Latest News

Press Release

LATEST

Sep 16, 2019

Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOxTM System for Chronic Bronchitis

Menlo Park, CA Sept. 16, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOxTM Bronchial RheoplastyTM system. RheOx uses a minimally-invasive procedure to deliver non-thermal energy to the airways to reduce...

Read More